Difference between revisions of "Juvenile myelomonocytic leukemia"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "'''contains dosing details in manuscript'''" to "'''dosing details in manuscript have been reviewed'''") |
Warner-admin (talk | contribs) m (Text replacement - "'''dosing details in manuscript have been reviewed'''" to "'''dosing details in manuscript have been reviewed by our editors'''") |
||
| Line 34: | Line 34: | ||
</div></div> | </div></div> | ||
===References=== | ===References=== | ||
| − | # '''AZA-JMML-001:''' Niemeyer CM, Flotho C, Lipka DB, Starý J, Rössig C, Baruchel A, Klingebiel T, Micalizzi C, Michel G, Nysom K, Rives S, Schmugge Liner M, Zecca M, Schönung M, Baumann I, Nöllke P, Benettaib B, Biserna N, Poon J, Simcock M, Patturajan M, Menezes D, Gaudy A, van den Heuvel-Eibrink MM, Locatelli F. Response to upfront azacitidine in juvenile myelomonocytic leukemia in the AZA-JMML-001 trial. Blood Adv. 2021 Jul 27;5(14):2901-2908. [https://doi.org/10.1182/bloodadvances.2020004144 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc8341358/ link to PMC article] '''dosing details in manuscript have been reviewed''' [https://pubmed.ncbi.nlm.nih.gov/34297046/ PubMed] [https://clinicaltrials.gov/study/NCT02447666 NCT02447666] | + | # '''AZA-JMML-001:''' Niemeyer CM, Flotho C, Lipka DB, Starý J, Rössig C, Baruchel A, Klingebiel T, Micalizzi C, Michel G, Nysom K, Rives S, Schmugge Liner M, Zecca M, Schönung M, Baumann I, Nöllke P, Benettaib B, Biserna N, Poon J, Simcock M, Patturajan M, Menezes D, Gaudy A, van den Heuvel-Eibrink MM, Locatelli F. Response to upfront azacitidine in juvenile myelomonocytic leukemia in the AZA-JMML-001 trial. Blood Adv. 2021 Jul 27;5(14):2901-2908. [https://doi.org/10.1182/bloodadvances.2020004144 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/pmc8341358/ link to PMC article] '''dosing details in manuscript have been reviewed by our editors''' [https://pubmed.ncbi.nlm.nih.gov/34297046/ PubMed] [https://clinicaltrials.gov/study/NCT02447666 NCT02447666] |
[[Category:Juvenile myelomonocytic leukemia regimens]] | [[Category:Juvenile myelomonocytic leukemia regimens]] | ||
Latest revision as of 12:26, 15 July 2024
| Section editor | |
|---|---|
 |
David Noyd, MD, MPH University of Washington Seattle, WA, USA |
1 regimens on this page
1 variants on this page
|
First-line therapy
Azacitidine monotherapy
Regimen
| Study | Dates of enrollment | Evidence |
|---|---|---|
| Niemeyer et al. 2021 (AZA-JMML-001) | 2015-2017 | Phase 2, fewer than 20 pts (RT) |
Chemotherapy
- Azacitidine (Vidaza) by the following age- and weight-based criteria:
- Less than 10 kg or younger than 1 year old: 2.5 mg/kg IV over 10 to 40 minutes once per day on days 1 to 7
- 10 kg or more and 1 year old or older: 75 mg/m2 IV once per day on days 1 to 7
28-day cycle for 3 to 6 cycles
References
- AZA-JMML-001: Niemeyer CM, Flotho C, Lipka DB, Starý J, Rössig C, Baruchel A, Klingebiel T, Micalizzi C, Michel G, Nysom K, Rives S, Schmugge Liner M, Zecca M, Schönung M, Baumann I, Nöllke P, Benettaib B, Biserna N, Poon J, Simcock M, Patturajan M, Menezes D, Gaudy A, van den Heuvel-Eibrink MM, Locatelli F. Response to upfront azacitidine in juvenile myelomonocytic leukemia in the AZA-JMML-001 trial. Blood Adv. 2021 Jul 27;5(14):2901-2908. link to original article link to PMC article dosing details in manuscript have been reviewed by our editors PubMed NCT02447666